SCHEMBL4095197

SCHEMBL4095197

NC(=O)c1c(N)cccc1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 4/20 0.39
MAOB P27338 1/20 0.39
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38
TYK2 P29597 1/20 0.38
SLC9A1 P19634 1/20 0.38
PARP1 P09874 1/20 0.38
NFKB1 P19838 1/20 0.37
SCN9A Q15858 3/20 0.36
AADAT Q8N5Z0 1/20 0.36
ERN1 O75460 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
RORB Q92753 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7878426 0.88 MAOB (0.42) PTGS1MAOBLMNAGAATYK2
SCHEMBL283130 0.85 HSD17B10 (0.41) PTGS1HTTHSD17B10LMNAGAA
Water SCHEMBL356237 0.83 HSD17B10 (0.41) PTGS1HTTHSD17B10LMNAGAA
Hydrochloric Acid SCHEMBL4454152 0.83 HSD17B10 (0.41) PTGS1HTTHSD17B10LMNAGAA
Hydrochloric Acid SCHEMBL9874294 0.81 THRB (0.39) PTGS1MAOBHTTHSD17B10LMNA
SCHEMBL3708513 0.81 CES2 (0.48) TYK2PARP1SCN9ARORB
SCHEMBL3716117 0.81 CA12 (0.43) MAOBHSD17B10LMNAGAATYK2
SCHEMBL8570598 0.80 CFTR (0.49) HSD17B10GAANFKB1KDM4EALDH1A1
SCHEMBL8200473 0.79 SCN9A (0.40) MAOBLMNAGAATYK2SLC9A1
Hydrochloric Acid SCHEMBL4371024 0.79 CES2 (0.47) TYK2PARP1SCN9ARORB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104903300-A Comt inhibitors HOFFMANN LA ROCHE 2015-09-09 CN disclosed
EP-1751118-B1 PYRIMIDINES FOR USE AS PLK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-12-03 EP disclosed
EP-1751118-B1 PYRIMIDINES FOR USE AS PLK INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-12-03 EP disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
US-7241769-B2 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-10 US disclosed
US-7241769-B2 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-10 US disclosed
US-7241769-B2 Pyrimidines as PLK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-07-10 US disclosed
EP-1180103-B1 RENIN INHIBITORS HOFFMANN LA ROCHE (CH) 2007-05-30 EP disclosed
EP-1751118-A1 PYRIMIDINES FOR USE AS PLK INHIBITORS Boehringer Ingelheim International GmbH (DE) 2007-02-14 EP disclosed
WO-2005113515-A1 PYRIMIDINES FOR USE AS PLK INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-01 WO disclosed
US-20050261295-A1 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-24 US disclosed
EP-1598343-A1 2-Arylaminopyrimidine derivatives as PLK inhibitors Boehringer Ingelheim International GmbH (DE) 2005-11-23 EP disclosed
US-5030727-A Reacting an anthronilide derivative with a thiazole derivative or a fluorozuinazolone with a neucleophile BASF AKTIENGESELLSCHAFT (DE) 1991-07-09 US disclosed
EP-0263523-A2 Process for the preparation of thiazolo [2,3-b] quinazolones BASF Aktiengesellschaft (DE) 1988-04-13 EP disclosed
US-4307113-A TREATMENT OF DIABETES SANDOZ, INC. (US) 1981-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 PTGS1 1070/4885MAOB 4179/4885HTT 4330/4885
US-20050261295-A1 2-Anilino-4-amino-, -oxy- or -thio-substituted, e.g., 2-(2-methoxy-4-N-propylcarbamoyl-phenylamino)-4-(2-carboxy-3-fluoro-phenylamino)-5-trifluoromethyl-pyrimidine; and 3-anilino--5-amino-, -oxy- or -thio-substituted 1,2,4-triazines; antiproliferative agents MKI67, CCNY, CCNO PTGS1 1315/4885MAOB 837/4885HTT 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.